NASDAQ:RCEL
AVITA Medical, Inc.
AVITA Medical, Inc.'s revenue grew 11.5% in fiscal 2025 to $71.6M while operating margin rose to −59.4%, its highest in 4 years. Free cash flow was −$32.2M, −45.0% of revenue, and the diluted share count rose 7.6%.Summary generated from AVITA Medical, Inc.'s SEC filings. Latest annual report filed Feb 12, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$71.6M
Revenue growth+11.5%
Revenue, 5-yr CAGRn/a
Gross margin82.1%
Operating margin−59.4%
Net margin−67.8%
ROIC−137.8%
Return on equityn/a
Debt / equityn/a
Free cash flow−$32.2M
FCF margin−45.0%
Share count change+7.6%
Financials
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 34 | 50 | 64 | 72 |
| Operating income | −28 | −43 | −57 | −43 |
| Net income | −27 | −35 | −62 | −49 |
| Free cash flow | −20 | −39 | −58 | −32 |
Recent filings
- 8-KEntry into a material agreement
Aug 11, 2026 - 8-K/AAmended results of a shareholder vote
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 4Insider transaction report
Jun 12, 2026 - 4Insider transaction report
Jun 10, 2026 - 8-KEntry into a material agreement
Jun 8, 2026 - 8-KDirector or officer change
Jun 4, 2026